MARLBOROUGH, Mass.,
Sept. 30, 2016 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) announced today that breast cancer
survivor and Grammy Award-winner Sheryl
Crow will join Steve
MacMillan, the Company's Chairman, President and Chief
Executive Officer, to ring the Nasdaq Opening Bell on October 3, in conjunction with the start of
Breast Cancer Awareness Month.
Hologic's participation in the bell ringing marks the start of a
month-long series of national events and media appearances to
increase awareness of the Genius™ 3D MAMMOGRAPHY™ exam, the only
mammogram clinically proven to detect cancer 15 months earlier than
traditional 2D screenings.i The Genius™ exam also has
been shown to reduce unnecessary callbacks by up to 40 percent, and
detect 41 percent more invasive cancers than conventional
mammography alone.ii,iii
"We are honored to ring in Breast Cancer Awareness Month with
our spokeswoman, Sheryl Crow, who
shares Hologic's steadfast commitment to educating women on the
importance of early detection," said MacMillan. "Early detection
saves lives, and our hope is that by the end of this month every
woman across the country knows that a more accurate mammogram, the
Genius™ exam, finds more invasive cancers, faster, than traditional
mammography."
Crow, a breast cancer survivor marking 10 years since her
diagnosis, will participate in a series of national and regional
media interviews throughout the month. In addition, Hologic teams
will educate women at a variety of events in 10 cities across the
nation, including Dallas, TX,
Phoenix, AZ, Birmingham, AL, and Pittsburgh, PA. The Company also will sponsor
American Cancer Society Making Strides Against Breast Cancer and
Susan G. Koman Race for the Cure
walks in multiple markets where Hologic sites are located. Hologic
will support these efforts with a national advertising campaign
featuring Crow via print, billboard and online ad placements. All
campaign materials will drive consumers to a microsite where women
can learn more about the technology and find imaging sites offering
the Genius™ exam.
"Ten years ago, I was diagnosed with breast cancer after a
routine mammogram," said Crow. "Fortunately, it was caught early
and I'm now cancer-free. I'm proud to be working with Hologic
during Breast Cancer Awareness Month to urge women to take
advantage of the best, and most accurate, screening technologies
available."
Genius™ 3D MAMMOGRAPHY™ exams have been available in the U.S.
since 2011, and are only available on the Hologic
Selenia® Dimensions® mammography system. More
than 100 clinical studies have proven the effectiveness of this
exam and in 2015, an estimated 10 million women in the U.S.
benefited from a Genius™ exam. Additional information, as well
as a locator to find imaging sites offering the exams, can be found
at http://Genius3DNearMe.com.
Webcast Information
Hologic's participation in the
Nasdaq Opening Bell ceremony will be aired live at
https://new.livestream.com/NASDAQ/live and with closed captioning
on the Nasdaq MarketSite tower in Times Square. A video of
the Opening Bell ceremony will be archived for one year on the
Nasdaq site.
About Hologic
Hologic, Inc. is a leading developer,
manufacturer and supplier of premium diagnostic products, medical
imaging systems and surgical products. The Company's core business
units focus on diagnostics, breast health, GYN surgical and
skeletal health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, 3D, 3D Mammography, Dimensions, Genius, Selenia, and
The Science of Sure are trademarks and/or registered trademarks of
Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may
contain forward-looking information that involves risks and
uncertainties, including statements about the use of Hologic
mammography systems. There can be no assurance the systems will
achieve the benefits described here, or that such benefits will be
replicated in any particular manner with respect to an individual
patient. The actual effect of the use of the systems can only be
determined on a case-by-case basis depending on the particular
circumstances and patient in question. In addition, there can be no
assurance that the systems will achieve any expected level of sales
or market share. Hologic expressly disclaims any obligation to
release publicly any updates to the data or statements presented
here to reflect any change in the Company's expectations or any
change in events, conditions or circumstances on which any such
data or statements are based.
Media Contacts:
Jane
Mazur
Hologic
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Emily Pan
Nasdaq
646.441.5120
Social Media Contact:
Joshua
Machiz
Nasdaq
212.231.5614
Investor Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com
______________________________
i McDonald ES, Oustimov A, Weinstein SP, et al.
Effectiveness of Digital Breast Tomosynthesis Compared With Digital
Mammography. JAMA Oncol. 2016.
ii Friedewald SM, Rafferty EA, Rose SL, et al. Breast
cancer screening using tomosynthesis in combination with digital
mammography. JAMA. 2014;311(24):2499-2507.
iii Rose SL, Tidwell AL, Bujnoch LJ, et al.
Implementation of breast tomosynthesis in a routine screening
practice: an observational study. AJR Am J Roentgenol.
2013;200(6):1401-1408.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-ceo-steve-macmillan-and-grammy-award-winner-and-breast-cancer-survivor-sheryl-crow-kick-off-breast-cancer-awareness-month-by-ringing-the-nasdaq-opening-bell-on-october-3-300336207.html
SOURCE Hologic, Inc.